Phase II trial of thalidomide, irinotecan and gemcitabine in chemonaive patients with advanced non-small cell lung cancer

A. R. Jazieh, R. Komrokji, A. Gupta, S. Patil, D. Flora, M. Knapp, M. Issa, Nagla Fawzy Miligy Abdel Karim

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

This study aim was to determine the efficacy and safety of the combination of Gemcitabine 1000mg/m2 day 1 & 8 and Irinotecan 100 mg/m 2 day 1 & 8 with escalating dose of thalidomide in chemonaive patients with advanced non-small cell lung cancer. Among the 20 patients who met eligibility criteria and received treatment, two patients (10) experienced partial response and 14 (70) experienced stable disease. The median time to disease progression was 4 months (95 CI: 2.86.6). The 1 year and 2 year survival rates were 36 and 27, respectively. This combination is active in advanced NSCLC with manageable toxicity profile.

Original languageEnglish (US)
Pages (from-to)932-936
Number of pages5
JournalCancer Investigation
Volume27
Issue number9
DOIs
StatePublished - Oct 22 2009
Externally publishedYes

Fingerprint

irinotecan
gemcitabine
Thalidomide
Non-Small Cell Lung Carcinoma
Disease Progression
Survival Rate
Safety

Keywords

  • Angiogenesis inhibitor
  • Chemotherapy
  • Thalidomide, non small cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Phase II trial of thalidomide, irinotecan and gemcitabine in chemonaive patients with advanced non-small cell lung cancer. / Jazieh, A. R.; Komrokji, R.; Gupta, A.; Patil, S.; Flora, D.; Knapp, M.; Issa, M.; Abdel Karim, Nagla Fawzy Miligy.

In: Cancer Investigation, Vol. 27, No. 9, 22.10.2009, p. 932-936.

Research output: Contribution to journalArticle

Jazieh, A. R. ; Komrokji, R. ; Gupta, A. ; Patil, S. ; Flora, D. ; Knapp, M. ; Issa, M. ; Abdel Karim, Nagla Fawzy Miligy. / Phase II trial of thalidomide, irinotecan and gemcitabine in chemonaive patients with advanced non-small cell lung cancer. In: Cancer Investigation. 2009 ; Vol. 27, No. 9. pp. 932-936.
@article{3faeb1622df04f99ac216ab2ddd95fe4,
title = "Phase II trial of thalidomide, irinotecan and gemcitabine in chemonaive patients with advanced non-small cell lung cancer",
abstract = "This study aim was to determine the efficacy and safety of the combination of Gemcitabine 1000mg/m2 day 1 & 8 and Irinotecan 100 mg/m 2 day 1 & 8 with escalating dose of thalidomide in chemonaive patients with advanced non-small cell lung cancer. Among the 20 patients who met eligibility criteria and received treatment, two patients (10) experienced partial response and 14 (70) experienced stable disease. The median time to disease progression was 4 months (95 CI: 2.86.6). The 1 year and 2 year survival rates were 36 and 27, respectively. This combination is active in advanced NSCLC with manageable toxicity profile.",
keywords = "Angiogenesis inhibitor, Chemotherapy, Thalidomide, non small cell lung cancer",
author = "Jazieh, {A. R.} and R. Komrokji and A. Gupta and S. Patil and D. Flora and M. Knapp and M. Issa and {Abdel Karim}, {Nagla Fawzy Miligy}",
year = "2009",
month = "10",
day = "22",
doi = "10.3109/07357900801944856",
language = "English (US)",
volume = "27",
pages = "932--936",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - Phase II trial of thalidomide, irinotecan and gemcitabine in chemonaive patients with advanced non-small cell lung cancer

AU - Jazieh, A. R.

AU - Komrokji, R.

AU - Gupta, A.

AU - Patil, S.

AU - Flora, D.

AU - Knapp, M.

AU - Issa, M.

AU - Abdel Karim, Nagla Fawzy Miligy

PY - 2009/10/22

Y1 - 2009/10/22

N2 - This study aim was to determine the efficacy and safety of the combination of Gemcitabine 1000mg/m2 day 1 & 8 and Irinotecan 100 mg/m 2 day 1 & 8 with escalating dose of thalidomide in chemonaive patients with advanced non-small cell lung cancer. Among the 20 patients who met eligibility criteria and received treatment, two patients (10) experienced partial response and 14 (70) experienced stable disease. The median time to disease progression was 4 months (95 CI: 2.86.6). The 1 year and 2 year survival rates were 36 and 27, respectively. This combination is active in advanced NSCLC with manageable toxicity profile.

AB - This study aim was to determine the efficacy and safety of the combination of Gemcitabine 1000mg/m2 day 1 & 8 and Irinotecan 100 mg/m 2 day 1 & 8 with escalating dose of thalidomide in chemonaive patients with advanced non-small cell lung cancer. Among the 20 patients who met eligibility criteria and received treatment, two patients (10) experienced partial response and 14 (70) experienced stable disease. The median time to disease progression was 4 months (95 CI: 2.86.6). The 1 year and 2 year survival rates were 36 and 27, respectively. This combination is active in advanced NSCLC with manageable toxicity profile.

KW - Angiogenesis inhibitor

KW - Chemotherapy

KW - Thalidomide, non small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=70350158634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350158634&partnerID=8YFLogxK

U2 - 10.3109/07357900801944856

DO - 10.3109/07357900801944856

M3 - Article

C2 - 19832041

AN - SCOPUS:70350158634

VL - 27

SP - 932

EP - 936

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 9

ER -